Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Equity Average (2016 - 2025)

Historic Equity Average for Ani Pharmaceuticals (ANIP) over the last 15 years, with Q3 2025 value amounting to $471.3 million.

  • Ani Pharmaceuticals' Equity Average fell 249.16% to $471.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $471.3 million, marking a year-over-year decrease of 249.16%. This contributed to the annual value of $458.9 million for FY2024, which is 2.41% down from last year.
  • Ani Pharmaceuticals' Equity Average amounted to $471.3 million in Q3 2025, which was down 249.16% from $427.7 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Equity Average peaked at $483.3 million during Q3 2024, and registered a low of $191.7 million during Q3 2021.
  • Over the past 5 years, Ani Pharmaceuticals' median Equity Average value was $401.6 million (recorded in 2022), while the average stood at $381.6 million.
  • Its Equity Average has fluctuated over the past 5 years, first surged by 10725.22% in 2022, then plummeted by 1488.16% in 2025.
  • Ani Pharmaceuticals' Equity Average (Quarter) stood at $289.6 million in 2021, then skyrocketed by 38.68% to $401.6 million in 2022, then rose by 17.51% to $472.0 million in 2023, then decreased by 3.11% to $457.3 million in 2024, then rose by 3.06% to $471.3 million in 2025.
  • Its last three reported values are $471.3 million in Q3 2025, $427.7 million for Q2 2025, and $411.2 million during Q1 2025.